30 Sep Rocket Pharmaceuticals
Raj Prabhakar, Chief Business Officer
Oct. 11 | 2:00pm | Aseptic Technologies Ballroom
Cranbury, NJ
(NASDAQ: RCKT)
Rocket is a clinical-stage, multi-platform (LVV & AAV) biotechnology company focused on the development of first, only and best-in-class gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating diseases. Rocket’s clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections, and Pyruvate Kinase Deficiency (PKD), a rare, monogenic red blood cell disorder resulting in mild to life-threatening anemia. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon Disease, a devastating, pediatric heart failure condition. Rocket also has received IND clearance for the AAV-based gene therapy program for PKP2-arrhythmogenic cardiomyopathy (ACM) and is advancing a preclinical program for BAG3-associated dilated cardiomyopathy (DCM).
